drugset / Trial / NCT06992258

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

NCT06992258

Phase 2 Recruiting 120 enrolled Criterium, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer

Timeline

Start
2025-10-27
Primary completion
2027-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule
Subject TAS-102 Small molecule

Indications